PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- The Christie NHS Foundation Trust
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Patient Experience and Preference
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Detailed Description
People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants with confirmed MM (per standard disease specific diagnostic criteria)
- •Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
- •Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
- •Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
- •Aged 18 years of age or over
- •Able to provide informed consent
- •Able to communicate in English
Exclusion Criteria
- •Aged under 18
- •Unable to understand and communicate in the English language
- •Unable to provide written informed consent
Outcomes
Primary Outcomes
Patient Experience and Preference
Time Frame: 30-60 minutes
The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
Secondary Outcomes
- Treatment and Preference Differences(30-60 minutes)